Microwave ablation compared with radiofrequency ablation for the treatment of liver cancer: a systematic review and meta-analysis

Guidelines have reported that although microwave ablation (MWA) has potential advantages over radiofrequency ablation (RFA), superiority in efficacy and safety remain unclear. Aim of the study is to compare MWA with RFA in the treatment of liver cancer. Meta-analysis was conducted according to the P...

Full description

Saved in:
Bibliographic Details
Published inRadiology and oncology Vol. 55; no. 3; pp. 247 - 258
Main Authors Spiliotis, Antonios E., Gäbelein, Gereon, Holländer, Sebastian, Scherber, Philipp-Robert, Glanemann, Matthias, Patel, Bijendra
Format Journal Article
LanguageEnglish
Published Poland Sciendo 25.06.2021
De Gruyter Poland
Subjects
Online AccessGet full text
ISSN1581-3207
1318-2099
1581-3207
0485-893X
DOI10.2478/raon-2021-0030

Cover

More Information
Summary:Guidelines have reported that although microwave ablation (MWA) has potential advantages over radiofrequency ablation (RFA), superiority in efficacy and safety remain unclear. Aim of the study is to compare MWA with RFA in the treatment of liver cancer. Meta-analysis was conducted according to the PRISMA guidelines for studies published from 2010 onwards. A random-effects model was used for the meta-analyses. Complete ablation (CA), local tumor progression (LTP), intrahepatic distant recurrence (IDR), and complications were analyzed. Four randomized trials and 11 observational studies with a total of 2,169 patients met the inclusion criteria. Although overall analysis showed no significant difference in LTP between MWA and RFA, subgroup analysis including randomized trials for patients with hepatocellular cancer (HCC) demonstrated statistically decreased rates of LTP in favor of MWA (OR, 0.40; 95% CI, 0.18-0.92; = 0.03). No significant differences were found between the two procedures in CA, IDR, complications, and tumor diameter less or larger than 3 cm. MWA showed promising results and demonstrated better oncological outcomes in terms of LTP compared to RFA in patients with HCC. MWA can be utilized as the ablation method of choice in patients with HCC.
Bibliography:ObjectType-Article-1
ObjectType-Evidence Based Healthcare-3
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ObjectType-Undefined-3
ISSN:1581-3207
1318-2099
1581-3207
0485-893X
DOI:10.2478/raon-2021-0030